623155-19-1

Basic information

• Product Name: 3-amino-N-cyclopropyl-4-methylbenzamide
• Synonyms: 3-amino-N-cyclopropyl-4-methylbenzamide
• CAS NO: 623155-19-1
• Molecular Formula: C₁₁H₁₄N₂O
• Molecular Weight: 190.24166
• Mol File: 623155-19-1.mol
• Article Data: 14

Chemical Properties

• Appearance: /
• CAS DataBase Reference: 3-amino-N-cyclopropyl-4-methylbenzamide(CAS DataBase Reference)
• NIST Chemistry Reference: 3-amino-N-cyclopropyl-4-methylbenzamide(623155-19-1)
• EPA Substance Registry System: 3-amino-N-cyclopropyl-4-methylbenzamide(623155-19-1)

Safety Data

• Hazardous Substances Data: 623155-19-1(Hazardous Substances Data)

Usage

General Description

3-amino-N-cyclopropyl-4-methylbenzamide is a chemical compound that consists of a benzene ring with a methyl group and an amine group attached to it. The cyclopropyl group is also attached to the amine group. It is commonly used in pharmaceutical research and drug development, particularly for its potential as an analgesic and anti-inflammatory agent. 3-amino-N-cyclopropyl-4-methylbenzamide has shown promise in studies for its ability to modulate pain and inflammation, making it a potentially valuable candidate for the development of new drugs for the treatment of various conditions. Its chemical structure and properties make it a valuable tool for research in the field of medicinal chemistry and pharmacology.

Upstream product

• 2458-12-0 3-amino-p-toluic acid 
• 2592-95-2 benzotriazol-1-ol 
• 765-30-0 Cyclopropylamine 
• 303133-89-3 N-cyclopropyl-4-methyl-3-nitrobenzamide 
• 96-98-0 4-methyl-3-nitrobenzoic acid 
• 10397-30-5 4-methyl-3-nitrobenzoyl chloride 

Downstream Products

• 851847-38-6 3-chloro-N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-2-nitrobenzamide 
• 851848-01-6 N-cyclopropyl-4-methyl-3-[(2-nitrobenzoyl)amino]benzamide 
• 851847-23-9 N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-4-methoxy-2-nitrobenzamide 
• 851846-86-1 5-chloro-N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-2-nitrobenzamide 
• 851847-21-7 N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-4-fluoro-2-nitrobenzamide 
• 857355-33-0 6-chloro-N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}nicotinamide 
• 857355-35-2 N-{5-[(cyclopropylamino)carbonyl]-2-methylphenyl}-2-(methylthio)pyrimidine-5-carboxamide 
• 858359-57-6 3-(5-amino-6-chloro-pyrimidin-4-ylamino)-N-cyclopropyl-4-methyl-benzamide 
• 623152-11-4 ethyl 4-(5-(cyclopropylcarbamoyl)-2-methylphenylamino)-5-methylpyrrolo[1,2-f][1,2,4]triazine-6-carboxylate 
• 623152-48-7 C₂₅H₂₃N₅O₂ 
• 623152-53-4 C₂₅H₂₄N₆O₂ 
• 895569-52-5 3-(allylamino)-N-cyclopropyl-4-methylbenzamide 
• 895569-30-9 3-(1,3-dioxo-3,4-dihydro-1H-isoquinolin-2-yl)-N-cyclopropyl-4-methylbenzamide 
• 895569-28-5 N-cyclopropyl-3-(7-methoxy-1,3-dioxo-3,4-dihydro-1H-isoquinolin-2-yl)-4-methylbenzamide 

Relevant articles and documents

Design, Synthesis, and Biological Evaluation of Novel Type I1/2 p38α MAP Kinase Inhibitors with Excellent Selectivity, High Potency, and Prolonged Target Residence Time by Interfering with the R-Spine

We recently reported 1a (skepinone-L) as a type I p38α MAP kinase inhibitor with high potency and excellent selectivity in vitro and in vivo. However, as a type I inhibitor, it is entirely ATP-competitive and shows just a moderate residence time. Thus, the scope was to develop a new class of advanced compounds maintaining the structural binding features of skepinone-L scaffold like inducing a glycine flip at the hinge region and occupying both hydrophobic regions I and II. Extending this scaffold with suitable residues resulted in an interference with the kinase's R-Spine. By synthesizing 69 compounds, we could significantly prolong the target residence time with one example to 3663 s, along with an excellent selectivity score of 0.006 and an outstanding potency of 1.0 nM. This new binding mode was validated by cocrystallization, showing all binding interactions typifying type I1/2 binding. Moreover, microsomal studies showed convenient metabolic stability of the most potent, herein reported representatives.

Bicyclic Derivatives as P38 Inhibitors

New bicyclic derivatives of formula (I); wherein the meanings for the various substituents are as disclosed in the description. These compounds are useful as p38 kinase inhibitors.

CYCLOPROPYL BENZAMIDE DERIVATIVES AS INTERMEDIATES FOR CYTOKINE INHIBITORS

A process for preparing a compound of formula (I) or a pharmaceutically acceptable salt thereof; wherein Qa is as defined in the specification, the compounds being useful in the preparation of therapeutic agents, in particular cytokine inhibitors. Novel compounds of formula (I) are also provided.